佐々木　祐典 (ササキ　マサノリ)

写真a

所属

附属再生医学研究所 神経再生医療学部門

職名

准教授

ホームページ

http://kaken.nii.ac.jp/d/r/20538136.ja.html

このページの先頭へ▲

経歴 【 表示 ／ 非表示 】

  • 2023年11月
    -
    継続中

    札幌医科大学   医学部 附属再生医学研究所   准教授

  • 2020年04月
    -
    2023年10月

    札幌医科大学   医学部 附属フロンティア医学研究所   准教授

  • 2012年08月
    -
    2020年03月

    札幌医科大学   医学部 附属フロンティア医学研究所   講師

  • 2012年01月
    -
    2012年07月

    札幌医科大学 医学部   医学部 附属フロンティア医学研究所   助教

このページの先頭へ▲

研究分野 【 表示 ／ 非表示 】

  • ライフサイエンス   脳神経外科学  

このページの先頭へ▲

researchmapの所属 【 表示 ／ 非表示 】

  • 札幌医科大学   医学部 附属再生医学研究所   准教授  

このページの先頭へ▲
 

論文 【 表示 ／ 非表示 】

  • Intravenous infusion of auto-serum-expanded autologous mesenchymal stem cells into chronic severe brain injury patients

    Tomohiro Yamaki, Shinichi Oka, Satoshi Iyama, Masanori Sasaki, Rie Onodera, Yuko Kataoka-Sasaki, Takahiro Namioka, Ai Namioka, Masahito Nakazaki, Mitsuhiro Takemura, Ryo Ukai, Takahiro Yokoyama, Yuichi Sasaki, Tatsuro Yamashita, Masato Kobayashi, Misako Yamaguchi, Marina Fukino, Taro Takazawa, Megumi Hayasaka, Takamitsu Owaku, Mika Funakura, Shinji Onodera, Yoichi M. Ito, Masayoshi Kobune, Junji Kato, Sumio Ishiai, Jeffery D. Kocsis, Masaru Odaki, Yasuo Iwadate, Shigeki Kobayashi, Osamu Honmou

    Interdisciplinary Neurosurgery ( Elsevier BV )  36   101927 - 101927  2024年06月

    DOI

  • Rehabilitation facilitates functional improvement following intravenous infusion of mesenchymal stem cells in the chronic phase of cerebral ischemia in rats.

    Tatsuro Yamashita, Masanori Sasaki, Yuichi Sasaki, Hiroshi Nagahama, Shinichi Oka, Yuko Kataoka-Sasaki, Ryo Ukai, Takahiro Yokoyama, Masato Kobayashi, Masafumi Kakizawa, Jeffery D Kocsis, Osamu Honmou

    Brain research   1825   148709 - 148709  2024年02月  [国際誌]

    　概要を見る

    The primary objective of this study was to investigate the potential facilitating effects of daily rehabilitation for chronic cerebral ischemia following the intravenous infusion of mesenchymal stem cells (MSC) in rats. The middle cerebral artery (MCA) was occluded by intraluminal occlusion using a microfilament (MCAO). Eight weeks after MCAO induction, the rats were used as a chronic cerebral ischemia model. Four experimental groups were studied: Vehicle group (medium only, no cells); Rehab group (vehicle + rehabilitation), MSC group (MSC only); and Combined group (MSC + rehabilitation). Rat MSCs were intravenously infused eight weeks after MCAO induction, and the rats received daily rehabilitation through treadmill exercise for 20 min. Behavioral testing, lesion volume assessment using magnetic resonance imaging (MRI), and histological analysis were performed during the observation period until 16 weeks after MCAO induction. All treated animals showed functional improvement compared with the Vehicle group; however, the therapeutic efficacy was greatest in the Combined group. The combination therapy is associated with enhanced neural plasticity shown with histological analysis and MRI diffusion tensor imaging. These findings provide behavioral evidence for enhanced recovery by combined therapy with rehabilitation and intravenous infusion of MSCs, and may form the basis for the development of clinical protocols in the future.

    DOI PubMed

  • Actin Alpha 2, Smooth Muscle (ACTA2) Is Involved in the Migratory Potential of Malignant Gliomas, and Its Increased Expression at Recurrence Is a Significant Adverse Prognostic Factor.

    Takumi Hoshimaru, Naosuke Nonoguchi, Takuya Kosaka, Motomasa Furuse, Shinji Kawabata, Ryokichi Yagi, Yoshitaka Kurisu, Hideki Kashiwagi, Masahiro Kameda, Toshihiro Takami, Yuko Kataoka-Sasaki, Masanori Sasaki, Osamu Honmou, Ryo Hiramatsu, Masahiko Wanibuchi

    Brain sciences   13 ( 10 )  2023年10月  [国際誌]

    　概要を見る

    Malignant glioma is a highly invasive tumor, and elucidating the glioma invasion mechanism is essential for developing novel therapies. We aimed to highlight actin alpha 2, smooth muscle (ACTA2) as potential biomarkers of brain invasion and distant recurrence in malignant gliomas. Using the human malignant glioma cell line, U251MG, we generated ACTA2 knockdown (KD) cells treated with small interfering RNA, and the cell motility and proliferation of the ACTA2 KD group were analyzed. Furthermore, tumor samples from 12 glioma patients who underwent reoperation at the time of tumor recurrence were utilized to measure ACTA2 expression in the tumors before and after recurrence. Thereafter, we examined how ACTA2 expression correlates with the time to tumor recurrence and the mode of recurrence. The results showed that the ACTA2 KD group demonstrated a decline in the mean motion distance and proliferative capacity compared to the control group. In the clinical glioma samples, ACTA2 expression was remarkably increased in recurrent samples compared to the primary samples from the same patients, and the higher the change in ACTCA2 expression from the start to relapse, the shorter the progression-free survival. In conclusion, ACTA2 may be involved in distant recurrence in clinical gliomas.

    DOI PubMed

  • Repeated intravenous infusion of mesenchymal stem cells enhances recovery of motor function in a rat model with chronic spinal cord injury.

    Kota Kurihara, Masanori Sasaki, Hiroshi Nagahama, Hisashi Obara, Ryunosuke Fukushi, Ryosuke Hirota, Mitsunori Yoshimoto, Atsushi Teramoto, Jeffery D Kocsis, Toshihiko Yamashita, Osamu Honmou

    Brain research   1817   148484 - 148484  2023年10月  [国際誌]

    　概要を見る

    Spinal cord injury (SCI) can cause paralysis with a high disease burden with limited treatment options. A single intravenous infusion of mesenchymal stem cells (MSCs) improves motor function in rat SCI models, possibly through the induction of axonal sprouting and remyelination. Repeated infusions (thrice at weekly intervals) of MSCs were administered to rats with chronic SCI to determine if multiple-dosing regimens enhance motor improvement. Chronic SCI rats were randomized and infused with vehicle (vehicle), single MSC injection at week 6 (MSC-1) or repeatedly injections of MSCs at 6, 7, and 8 weeks (MSC-3) after SCI induction. In addition, a single high dose of MSCs (HD-MSC) equivalent to thrice the single dose was infused at week 6. Locomotor function, light and electron microscopy, immunohistochemistry and ex vivo diffusion tensor imaging were performed. Repeated infusion of MSCs (MSC-3) provided the greatest functional recovery compared to single and single high-dose infusions. The density of remyelinated axons in the injured spinal cord was the greatest in the MSC-3 group, followed by the MSC-1, HD-MSC and vehicle groups. Increased sprouting of the corticospinal tract and serotonergic axon density was the greatest in the MSC-3 group, followed by MSC-1, HD-MSC, and vehicle groups. Repeated infusion of MSCs over three weeks resulted in greater functional improvement than single administration of MSCs, even when the number of infused cells was tripled. MSC-treated rats showed axonal sprouting and remyelination in the chronic phase of SCI.

    DOI PubMed

  • Mesenchymal Stem Cell Transplantation for Spinal Cord Injury: Current Status and Prospects

    Ryosuke Hirota, Masanori Sasaki, Osamu Honmou, Toshihiko Yamashita

    Spine Surgery and Related Research ( Japanese Society for Spine Surgery and Related Research )  7 ( 4 ) 319 - 326  2023年07月

    DOI

全件表示 >>

このページの先頭へ▲

Misc 【 表示 ／ 非表示 】

全件表示 >>

このページの先頭へ▲

共同研究・競争的資金等の研究課題 【 表示 ／ 非表示 】

  • 慢性期脳梗塞に対する骨髄幹細胞治療における至適リハビリ条件の探索

    基盤研究(C)

    研究期間:

    2024年04月
    -
    2027年03月
     

    山下 達郎, 佐々木 雄一, 佐々木 祐典, 鵜飼 亮, 岡 真一, 佐々木 優子, 本望 修, 中崎 公仁

  • 脳梗塞と脊髄損傷に対する中枢神経系全域の可塑性賦活化による治療戦略の検討

    基盤研究(B)

    研究期間:

    2024年04月
    -
    2025年03月
     

    本望 修, 佐々木 雄一, 福士 龍之介, 佐々木 祐典, 小原 尚, 鵜飼 亮, 小林 萬里, 山下 達郎, 横山 貴裕, 岡 真一, 佐々木 優子, 中崎 公仁

  • 新生児低酸素性虚血性脳症に対する次世代型エクソソームを用いた新規治療法の開発

    基盤研究(C)

    研究期間:

    2023年04月
    -
    2026年03月
     

    寺田 光次郎, 津川 毅, 飯塚 裕典, 佐々木 祐典, 長濱 宏史, 坂井 拓朗, 本望 修

  • 骨髄間葉系幹細胞移植による慢性腎臓病および連関する脳血管障害の同時進行抑制

    基盤研究(C)

    研究期間:

    2023年04月
    -
    2026年03月
     

    長岡 由修, 飯塚 裕典, 寺田 光次郎, 津川 毅, 佐々木 祐典, 本望 修

  • 骨髄間葉系幹細胞を用いた難治性てんかんの新規治療法開発とメカニズム解明

    基盤研究(C)

    研究期間:

    2022年04月
    -
    2025年03月
     

    福村 忍, 津川 毅, 佐々木 祐典, 長濱 宏史, 本望 修

全件表示 >>

このページの先頭へ▲